Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Clin Microbiol Infect. 2020 Feb 12;26(9):1207–1213. doi: 10.1016/j.cmi.2020.02.004

Figure 2: Model Fit of Dose-escalated Polymyxin B + Meropenem against CRAB.

Figure 2:

The post hoc fits for the full array of dose-escalated polymyxin B + 4 g meropenem 3h prolonged infusion q8h (lines) overlaid with observed data from the HFIM (points). Additionally, negative controls (growth control, polymyxin B monotherapy, and 4 g meropenem monotherapy) from the previous study by Lenhard et al. are also shown as reference on the finalized model’s performance.[20]